Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy

PHASE3CompletedINTERVENTIONAL

Enrollment

189

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

September 30, 2013

Conditions

Type 2 Diabetes

Interventions

DRUG

MP513

form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day

DRUG

Placebo

form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day

Trial Locations (1)

Handok Pharmaceuticals CO. LTD, Seoul